leadf
logo-loader
viewVolitionRx

VolitionRX chief delighted with first CE Mark in Europe

Cameron Reynolds, chief executive of VolitionRx (NYSE:VNRX) says he is delighted the firm has received a first CE Mark for a blood-based diagnostic assay, which paves the way for clinical sales in Europe.

The award is for NuQX001S, for detecting colorectal cancer.

It will allow the company to sell the assay in the 28 member states of the European Union, as well as Switzerland, Turkey, Iceland, Norway and Liechtenstein - an area with a total population of nearly 600 million people -  oh which 150 million are of screening age.

Quick facts: VolitionRx

Price: 4.1 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $197.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

VolitionRx Limited ends its 3Q with $21M in the bank, looks forward to...

VolitionRx Limited (NYSE AMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the group finished its third quarter with around $21M in the bank compared with $17M at the end of 2019. Reynolds also discussed upcoming milestones including the preparing to launch its new product, Nu.Q™ Vet Cancer...

on 11/13/2020

2 min read